Inhibitor Therapeutics, Inc.
INTI
$0.08
$0.0110.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.47% | -18.08% | 7.18% | -14.77% | 1.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.39% | -8.85% | 18.92% | -12.93% | 16.56% |
| Operating Income | 11.39% | 8.85% | -18.92% | 12.93% | -16.56% |
| Income Before Tax | 8.89% | 2.57% | -31.53% | 7.58% | -21.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.89% | 2.57% | -31.53% | 7.58% | -21.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.89% | 2.57% | -31.53% | 7.58% | -21.80% |
| EBIT | 11.39% | 8.85% | -18.92% | 12.93% | -16.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.64% | 2.38% | -31.03% | 7.50% | -22.06% |
| Normalized Basic EPS | 9.62% | 3.70% | -33.33% | 8.00% | -23.81% |
| EPS Diluted | 9.64% | 2.38% | -31.03% | 7.50% | -22.06% |
| Normalized Diluted EPS | 9.62% | 3.70% | -33.33% | 8.00% | -23.81% |
| Average Basic Shares Outstanding | 0.15% | 0.15% | 0.15% | 0.14% | 0.17% |
| Average Diluted Shares Outstanding | 0.15% | 0.15% | 0.15% | 0.14% | 0.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |